Compare BHR & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | ATRA |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 94.2M |
| IPO Year | 2013 | 2014 |
| Metric | BHR | ATRA |
|---|---|---|
| Price | $1.43 | $9.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | ★ 680.5K | 27.8K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $487,614,000.00 | $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,334.59 |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.18 | $3.92 |
| 52 Week High | $3.19 | $19.15 |
| Indicator | BHR | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 50.08 |
| Support Level | $1.18 | $8.94 |
| Resistance Level | $2.61 | $9.93 |
| Average True Range (ATR) | 0.11 | 0.56 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 54.17 | 36.14 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.